Mirela Sedić

8PUBLICATIONS
12CO-AUTHORS
Molecular targetsBiologically active moleculesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 26, 2023
Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro.

Iris Car, Antje Dittmann, Olga Vasieva

|Apr 28, 2023
Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib.

Iris Car, Antje Dittmann, Marko Klobučar

|Nov 27, 2021
Amidine- and Amidoxime-Substituted Heterocycles: Synthesis, Antiproliferative Evaluations and DNA Binding.

Silvija Maračić, Petra Grbčić, Suresh Shammugam

|Oct 13, 2021
The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.

Petra Grbčić, Thomas O Eichmann, Sandra Kraljević Pavelić

|Jul 02, 2021
Novel Bis- and Mono-Pyrrolo[2,3-d]pyrimidine and Purine Derivatives: Synthesis, Computational Analysis and Antiproliferative Evaluation.

Andrea Bistrović Popov, Robert Vianelo, Petra Grbčić

|Jul 02, 2021
Proteomic Profiling of BRAFV600E Mutant Colon Cancer Cells Reveals the Involvement of Nucleophosmin/c-Myc Axis in Modulating the Response and Resistance to BRAF Inhibition by Vemurafenib.

Petra Grbčić, Dora Fučkar Čupić, Tania Gamberi

Pageof 2

Frequent Collaborators

6 joint publications

Sandra Kraljević Pavelić

5 joint publications

Petra Grbčić

2 joint publications

Krešimir Pavelić

2 joint publications

Silvana Raić-Malić